{"id":812970,"date":"2022-08-08T19:14:25","date_gmt":"2022-08-08T17:14:25","guid":{"rendered":"https:\/\/15.161.165.86\/non-categorizzato\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"modified":"2022-08-08T19:14:25","modified_gmt":"2022-08-08T17:14:25","slug":"verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/","title":{"rendered":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress"},"content":{"rendered":"Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +\/- Defactinib in Low-Grade Serous Ovarian Cancer; Continued Evaluation of Both Monotherapy and Combination Therapy with Timing of Go Forward Treatment Regimen Selection Driven by Data Maturity\n\n\nVerastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Addition to Standard of Care Chemotherapy in Front-Line Metastatic Pancreatic Cancer\n\n\nU.S. Patent and Trademark Office Granted Patent for Novel VS-6766 Dosing Regimen for Cancers with KRAS\/NRAS\/HRAS Mutations; Extending Patent Protection Through 2038\n\nBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical c<div class=\"leaky_paywall_message_wrap\"><div id=\"leaky_paywall_message\"><a href=\"https:\/\/bebeez.it\/abbonati\/\">Abbonati<\/a> o <a href=\"https:\/\/bebeez.it\/mio-account\/\">Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +\/- Defactinib in Low-Grade Serous Ovarian Cancer; Continued Evaluation of Both Monotherapy and Combination Therapy with Timing of Go Forward Treatment Regimen Selection Driven by Data Maturity Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-812970","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +\/- Defactinib in Low-Grade Serous Ovarian Cancer; Continued Evaluation of Both Monotherapy and Combination Therapy with Timing of Go Forward Treatment Regimen Selection Driven by Data Maturity Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-08T17:14:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress\",\"datePublished\":\"2022-08-08T17:14:25+00:00\",\"dateModified\":\"2022-08-08T17:14:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"},\"wordCount\":2546,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\",\"name\":\"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-08-08T17:14:25+00:00\",\"dateModified\":\"2022-08-08T17:14:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/","og_locale":"en_US","og_type":"article","og_title":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","og_description":"Company Reported Interim Findings from RAMP 201 Trial of VS-6766 +\/- Defactinib in Low-Grade Serous Ovarian Cancer; Continued Evaluation of Both Monotherapy and Combination Therapy with Timing of Go Forward Treatment Regimen Selection Driven by Data Maturity Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and [&hellip;]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/","og_site_name":"BeBeez","article_published_time":"2022-08-08T17:14:25+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"author":{"name":"","@id":""},"headline":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress","datePublished":"2022-08-08T17:14:25+00:00","dateModified":"2022-08-08T17:14:25+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/"},"wordCount":2546,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/","name":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-08-08T17:14:25+00:00","dateModified":"2022-08-08T17:14:25+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-company-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=812970"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812970\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=812970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=812970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=812970"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=812970"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=812970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}